AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics Inc is experiencing significant growth, particularly with its Auryon product, which is expanding its customer base in office-based labs (OBL) and hospital settings, contributing to improved average selling prices (ASP). The company is on track to enhance its gross margins, currently at 52.5%, through accelerated manufacturing initiatives and a favorable revenue mix that favors higher Med-Tech revenues, projected to finalize in January 2026. Additionally, management's confidence in sustained growth is underscored by the acquisition of new customers, increased utilization in existing accounts, and the ability to implement price increases across its product lines.

AngioDynamics Inc is facing significant financial challenges, as management has indicated expectations of $4M-$6M in tariff headwinds, which could negatively impact overall profitability. Furthermore, anticipated pressure on inventory from rising raw material costs in the second half of fiscal 2026 suggests potential challenges in maintaining healthy margins. While recent quarterly performance has seen positive results from capital sales, uncertainties around future disposable demand and increasing costs raise concerns about sustaining growth moving forward.